Literature DB >> 11535872

Is type III intestinal metaplasia an obligatory precancerous lesion in intestinal-type gastric carcinoma?

J M Conchillo1, G Houben, A de Bruïne, R Stockbrügger.   

Abstract

This retrospective study was performed to assess whether type III intestinal metaplasia is an obligatory precancerous lesion of intestinal-type gastric carcinoma and to determine its possible use as a marker of enhanced cancer risk. From 48 consecutive patients with gastric cancer who underwent a gastrectomy over a 3-year period (mean age 72.0 years; 29 M/19 F), at least two sections from antrum, corpus and tumour-surrounding mucosa were obtained for the examination of presence and subtypes of intestinal metaplasia (IM). It was found that 77.1% of the carcinomas were of the intestinal type and 22.9% of the diffuse type. The intestinal-type was more often found in males (P = 0.01); the mean age at diagnosis in this type was higher than in the diffuse cancer group (P = 0.004). There was a high prevalence of total IM in both the intestinal (75.7%) and diffuse group (88.9%). Type I IM was predominant in antrum and corpus of patients from both groups. Type III IM was only found among patients with intestinal-type carcinoma. However, its prevalence was rather low (26.3%). Therefore the absence of this lesion in patients with other risk factors cannot be used as an argument for lowering the degree of surveillance and its presence seems to be sufficient indication for long-term follow-up.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11535872     DOI: 10.1097/00008469-200108000-00003

Source DB:  PubMed          Journal:  Eur J Cancer Prev        ISSN: 0959-8278            Impact factor:   2.497


  16 in total

1.  Dopamine and cAMP regulated phosphoprotein MW 32 kDa is overexpressed in early stages of gastric tumorigenesis.

Authors:  Kaushik Mukherjee; Dunfa Peng; Zaid Brifkani; Abbes Belkhiri; Manuel Pera; Tatsuki Koyama; Elizabeth A S Koehler; Frank L Revetta; Mary K Washington; Wael El-Rifai
Journal:  Surgery       Date:  2010-07-01       Impact factor: 3.982

Review 2.  Utility of subtyping intestinal metaplasia as marker of gastric cancer risk. A review of the evidence.

Authors:  Carlos A González; José M Sanz-Anquela; Javier P Gisbert; Pelayo Correa
Journal:  Int J Cancer       Date:  2013-02-05       Impact factor: 7.396

3.  Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED).

Authors:  M Dinis-Ribeiro; M Areia; A C de Vries; R Marcos-Pinto; M Monteiro-Soares; A O'Connor; C Pereira; P Pimentel-Nunes; R Correia; A Ensari; J M Dumonceau; J C Machado; G Macedo; P Malfertheiner; T Matysiak-Budnik; F Megraud; K Miki; C O'Morain; R M Peek; T Ponchon; A Ristimaki; B Rembacken; F Carneiro; E J Kuipers
Journal:  Virchows Arch       Date:  2011-12-22       Impact factor: 4.064

4.  Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED).

Authors:  M Dinis-Ribeiro; M Areia; A C de Vries; R Marcos-Pinto; M Monteiro-Soares; A O'Connor; C Pereira; P Pimentel-Nunes; R Correia; A Ensari; J M Dumonceau; J C Machado; G Macedo; P Malfertheiner; T Matysiak-Budnik; F Megraud; K Miki; C O'Morain; R M Peek; T Ponchon; A Ristimaki; B Rembacken; F Carneiro; E J Kuipers
Journal:  Endoscopy       Date:  2011-12-23       Impact factor: 10.093

Review 5.  Risk for gastric neoplasias in patients with chronic atrophic gastritis: a critical reappraisal.

Authors:  Lucy Vannella; Edith Lahner; Bruno Annibale
Journal:  World J Gastroenterol       Date:  2012-03-28       Impact factor: 5.742

6.  A follow up model for patients with atrophic chronic gastritis and intestinal metaplasia.

Authors:  M Dinis-Ribeiro; C Lopes; A da Costa-Pereira; M Guilherme; J Barbosa; H Lomba-Viana; R Silva; L Moreira-Dias
Journal:  J Clin Pathol       Date:  2004-02       Impact factor: 3.411

7.  Validity of serum pepsinogen I/II ratio for the diagnosis of gastric epithelial dysplasia and intestinal metaplasia during the follow-up of patients at risk for intestinal-type gastric adenocarcinoma.

Authors:  Mário Dinis-Ribeiro; Altamiro da Costa-Pereira; Carlos Lopes; Joana Barbosa; Mateus Guilherme; Luís Moreira-Dias; Helena Lomba-Viana; Rui Silva; Nuno Abreu; Rafael Lomba-Viana
Journal:  Neoplasia       Date:  2004 Sep-Oct       Impact factor: 5.715

8.  Helicobacter pylori infection generated gastric cancer through p53-Rb tumor-suppressor system mutation and telomerase reactivation.

Authors:  Jing Lan; Yong-Yan Xiong; Yi-Xian Lin; Bi-Cheng Wang; Ling-Ling Gong; Hui-Sen Xu; Guang-Song Guo
Journal:  World J Gastroenterol       Date:  2003-01       Impact factor: 5.742

9.  High-risk individuals for gastric cancer would be missed for surveillance without subtyping of intestinal metaplasia.

Authors:  Sergejs Isajevs; Selga Savcenko; Inta Liepniece-Karele; Maria Blanca Piazuelo; Ilze Kikuste; Ivars Tolmanis; Aigars Vanags; Indra Gulbe; Linda Mezmale; Darhan Samentaev; Altynbek Tazedinov; Ramis Samsutdinov; Tatjana Belihina; Nurbek Igissinov; Marcis Leja
Journal:  Virchows Arch       Date:  2021-05-14       Impact factor: 4.064

Review 10.  Histologic Subtyping of Gastric Intestinal Metaplasia: Overview and Considerations for Clinical Practice.

Authors:  Shailja C Shah; Andrew J Gawron; Reem A Mustafa; M Blanca Piazuelo
Journal:  Gastroenterology       Date:  2019-12-06       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.